FDA Clears AI-Enabled SmartHeart Cardiac MRI Software
Reportedly providing automation of 14 standard and advanced cardiac MRI views in less than 30 seconds, the SmartHeart also facilitates a 75 percent reduction in breath holds for basic MRI views.
The Food and Drug Administration (FDA) has issued 510(k) clearance for SmartHeart, an AI-powered software with enhanced automation that may significantly streamline cardiac MRI exams.
Philips, the manufacturer of SmartHeart, said the
The SmartHeart software offers the additional benefit of a 75 percent reduction in breath holds when capturing standard cardiac MRI views, which can be particularly advantageous for patients with dyspnea, arrhythmias or anxiety as well as pediatric patients, according to Philips.
The company noted that other key features with SmartHeart include Cardiac Motion Correction and CardiacQuant Perfusion, which aids in the detection of subtle perfusion deficits through quantitative evaluation of myocardial perfusion.
“Cardiac MR is one of the most powerful tools available to assess the heart, yet its complexity and exam length have historically constrained its broader clinical impact,” noted Ioannis Panagiotelis, Ph.D., the business leader of MR at Philips. “With SmartHeart embedded directly into the planning workflow, Philips is fundamentally redefining how (cardiac MR) is performed, transforming it from a highly specialized, time-intensive procedure into a streamlined, intelligent, and scalable solution.”
Related Content
